What works in medication reconciliation: an on-treatment and site analysis of the MARQUIS2 study

Jeffrey L Schnipper1,2,3, Harry Reyes Nieva4,2, Catherine Yoon4

  • 1Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital Department of Medicine, Boston, Massachusetts, USA jschnipper@bwh.harvard.edu.

BMJ Quality & Safety
|March 22, 2023
PubMed
Abstract

Insights

Patient-level interventions, like obtaining a best possible medication history in the ED and clinician-led reconciliation, significantly reduce medication discrepancies. System-level changes support these efforts for improved patient safety during care transitions.

Area of Science:

  • Health Services Research
  • Patient Safety
  • Medication Management

Background:

  • The second Multicenter Medication Reconciliation Quality Improvement Study showed reduced medication discrepancies.
  • This analysis investigates the impact of system-level and patient-level interventions on these outcomes.

Purpose of the Study:

  • To determine the association between patient exposure to system-level interventions and receipt of patient-level interventions with reduced medication discrepancies.
  • To identify which interventions are most effective in decreasing medication errors.

Main Methods:

  • An on-treatment analysis of system-level interventions using monthly surveys.
  • Analysis of patient-level interventions via pharmacist review of medical records.
  • Mixed-effects Poisson regression and GLMM decision trees were used to analyze associations.

Main Results:

  • Seven of eight system-level intervention categories and 15 individual components showed modest reductions in discrepancies.
  • Five of seven patient-level interventions significantly reduced discrepancies, notably a best possible medication history (BPMH) in the ED and clinician-led admission/discharge reconciliation.
  • Patients receiving both an ED BPMH and discharge reconciliation had the lowest discrepancy rates.

Conclusions:

  • Patient-level interventions, particularly obtaining a BPMH in the ED and clinician-led reconciliation, are most effective in reducing medication discrepancies.
  • System-level interventions play a supportive role and increase reach.
  • Findings guide prioritization of interventions to enhance medication safety during care transitions.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
151
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.7K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
16